PL EN


Preferences help
enabled [disable] Abstract
Number of results
2010 | 64 | 3-4 | 58-70
Article title

Przegląd doniesień na temat wpływu melatoniny na patogenezę i terapię raka piersi

Content
Title variants
EN
The news about the infl uence of melatonin on pathogenesis and therapy of breast cancer
Languages of publication
PL
Abstracts
EN
The main role of melatonin is regulation of circadian and seasonal rhythm. Recently there were carried out a lot of researches on the role and potential application of melatonin in prevention and therapy of various dismelaeases. This work is related to researches about the melatonin infl uence on estrogen-dependent breast cancer and application in treating this neoplasm. Probable oncostatic mechanisms i.e. melatonin acting as SERM, SEEM and its infl uence on the hypothalamic – pituitary – reproductive axis, was analyzed. Moreover the relation between circadian disruptions and increase in breast cancer risk were observed. The aim of this work is to show mechanisms melatonin acting and how we can use this hormone in oncology.
PL
Melatonina pełni przede wszystkim funkcję biochemicznego regulatora rytmów okołodobowych i sezonowych, ale szczególne zainteresowanie naukowców wzbudzają udowodnione już jej właściwości antyoksydacyjne i immunomodulujące oraz jej wpływ na regulację wydzielania innych hormonów. W ostatnich latach zostało przeprowadzonych wiele badań dotyczących roli oraz potencjalnego zastosowania melatoniny w profi laktyce i leczeniu różnych jednostek chorobowych. Praca jest przeglądem piśmiennictwa dotyczącego badań nad wpływem melatoniny na patogenezę raka sutka i jej terapeutycznego zastosowania w tym nowotworze. Badano prawdopodobne mechanizmy onkostatyczne dotyczące wpływu na oś podwzgórzowo-przysadkowo-gonadalną oraz działanie melatoniny jako selektywnego modulatora receptora estrogenowego (SERM) i enzymów biorących udział w biosyntezie estrogenów w tkankach obwodowych (SEEM). Ponadto zaobserwowano związek między zaburzeniami rytmu dobowego u kobiet a wzrostem ryzyka zachorowania na raka sutka. Celem niniejszej pracy jest przedstawienie mechanizmów działania melatoniny i jej zastosowania w onkologii.
Discipline
Publisher

Year
Volume
64
Issue
3-4
Pages
58-70
Physical description
Contributors
  • Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w KatowicachKatowice, ul. Ligocka 5/16, tel. +48 694 159 122, +48 505 597 250, kingagrabinska@interia.pl
  • Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach
  • Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach
author
  • Katedra i Klinika Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach
References
  • 1. Zawilska J.B., Nowak J.Z. Rytmika okołodobowa i zegar biologiczny. Sen. 2002; 2(4): 127–136.
  • 2. Arendt J. Melatonin and the pineal gland: infl uence on mammalian seasonal and circadian physiology. Reviews of Reproduction. 1998; 3: 13-22.
  • 3. Zawilska J.B., Nowak J.Z. Melatonin: from biochemistry to therapeutic applications. Pol. J. Pharmacol. 1999; 51: 3–23.
  • 4. Zawilska J.B., Nowak J.Z. Regulatory mechanisms in melatonin biosynthesis in retina. Neurochem. Int. 1992; 20: 23–36.
  • 5. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991; 12: 151–180.
  • 6. Nowak J.Z., Zawilska J.B. Melatonina jako koordynator rytmów biologicznych: regulacja biosyntezy, działania fi - zjologiczne i znaczenie terapeutyczne. Lęk i Depresja. 1996; 1: 189-211.
  • 7. Reiter R.J. Melatonin: the chemical expression of darkness. Mol. Cell. Endocrinol. 1991; 79: C153–C158.
  • 8. Stevens R.G. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int. J. Epidemiol. 2009; 38(4): 963-970.
  • 9. Lewczuk B. Siatkówka, jądro skrzyżowania oraz szyszynka jako elementy zegara biologicznego ssaków. Medycyna Wet. 2007; 63(5): 506-511.
  • 10. Hannibal J. Neurotransmitters of the retino-hypothalamic tract. Cell Tissue Res. 2002; 309: 73-88.
  • 11. Hannibal J., Ding J.M., Chen D., Fahrenkrug J., Larsen P.J., Gillette M.U., Mikkelsen J.D. Pituitary adenylate cyclase-activating peptide (PACAP) in the retinohypothalamic tract: a potential daytime regulator of the biological clock. J. Neurosci. 1997; 17: 2637-2644.
  • 12. Moore R.Y., Speh J.C., Leak R.K. Suprachiasmatic nucleus organization. Cell Tissue Res. 2002; 309: 89-98.
  • 13. Danielczyk K., Dziegiel P. MT1 melatonin receptors and their role in the oncostatic action of melatonin. Postępy Hig Med Dosw (Online). 2009; 63: 425-434.
  • 14. Cos S., González A., Martínez-Campa C., Mediavilla M.D, Alonso-González C., Sánchez-Barceló E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detection and Prevention. 2006; 30: 118-128.
  • 15. Blask D.E., Sauer L.A., Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002; 2(2): 113-132.
  • 16. Reiter R.J., Tan D.X., Terron M.P., Flores L.J., Czarnocki Z. Melatonin and its metabolites: new fi ndings regarding their production and their radical scavenging actions. Acta Biochim Pol. 2007; 54(1): 1-9.
  • 17. Karasek M. Szyszynka i melatonina. Wydawnictwo Naukowe PWN, Warszawa –Łódź 1997.
  • 18. Dziegiel P., Podhorska-Okołów M., Zabel M. Melatonin: adjuvant therapy of malignant tumors. Med Sci Monit. 2008; 14(5): RA64-70.
  • 19. Girgert R., Hanf V., Emons G., Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res. 2009; 47: 23-31.
  • 20. Hill S.M., Frasch T., Xiang S., Yuan L., Duplessis T., Mao L. Molecular mechanisms of melatonin anticancer eff ects. Integr Cancer Ther. 2009; 8(4): 337-346.
  • 21. Solár P. Melatonin and its wide-spectrum eff ects: use of melatonin in the treatment of tumors. Cesk Fysiol. 1999; 48(1): 27-40.
  • 22. Moss R.W. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther. 2007; 6(3): 281-292.
  • 23. Bilski B. Czy praca zmianowa jest czynnikiem ryzyka choroby nowotworowej? Medycyna Pracy. 2005; 56(2): 175-178.
  • 24. Rögelsperger O., Ekmekcioglu C., Jäger W. i wsp. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009; 46(4): 422-432.
  • 25. Cucina A., Proietti S., D’Anselmi F., Coluccia P., Dinicola S., Frati L., Bizzarri M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res. 2009; 46(2): 172-180.
  • 26. Dillon D.C., Easley S.E., Asch B.B. i wsp. Diff erential expression of high-affi nity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002; 118(3): 451-8.
  • 27. Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Sánchez-Barceló E.J. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008; 8: 691-702.
  • 28. Mediavilla M.D., Cos S., Sánchez- Barceló E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999; 65(4): 415-420.
  • 29. Blask D.E. Melatonin, sleep disturbance and cancer risk, 2008; 13: 257-264.
  • 30. Blask D.E., Dauchy R.T., Brainard G.C., Hanifi n J.P. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther. 2009; 8(4): 347-353.
  • 31. Srinivasan V., Spence D.W., Pandi-Perumal S.R., Trakht I., Cardinali D.P. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008; 7(3): 189-203.
  • 32. Jassem J., Bobek-Biliewicz B., Krzakowski M. i wsp. Rak Piersi. Krzakowski M., Herman K., Jassem J. i wsp. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – 2009. Część I. Via Medica, Gdańsk 2009: 185- 231.
  • 33. Feigelson H.S., Henderson B.E. Estrogens and breast cancer. Carcinogenesis. 1996; 17: 2279-2284.
  • 34. Russo I.H., Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998; 3: 49–61.
  • 35. Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985; 45: 2900–2906.
  • 36. Yue W., Wang J.P., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998;58:927–32.
  • 37. Yue W., Santen R.J., Wang J.P. i wsp. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003; 86: 477–486.
  • 38. Wong Z.W., Ellis M.J. First-line endocrine treatment of breast cancer: aromatase inhibitor or antiestrogen? Br J Cancer. 2004; 90: 20–25.
  • 39. Molis T.M., Spriggs L.L., Hill S.M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 1994; 8: 1681–1690.
  • 40. Molis T.M., Walters M.R., Hill S.M. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cancer cells. Int J Oncol. 1993; 3: 687–694.
  • 41. Rato A.G., Pedrero J.G., Martinez M.A., del Rio B., Lazo P.S., Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 1999; 13: 857–868.
  • 42. Aronika S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signalling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA. 1994; 91: 8517–8521.
  • 43. Kiefer T., Ram P.T., Yuan L., Hill S.M. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat. 2002; 71: 37–45.
  • 44. Dai J., Inscho E.W., Yuan L., Hill S.M. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res. 2002; 32: 112–9.
  • 45. Del Rio B., Garcı´a-Pedrero J.M., Martı´nez-Campa C., Zuazua P., Lazo P.S., Ramos S. Melatonin: an endogenous specifi c inhibitor of estrogen receptor a via calmodulin. J Biol Chem. 2004;.279: 38294–38302.
  • 46. Cos S., Martı´nez-Campa C., Mediavilla M.D., Sa¨nchez-Barcelo´ E.J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005; 38: 136–142.
  • 47. Reiter R.J., Tan D.X., Erren T.C., Fuentes- Broto L., Paredes S.D. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther. 2009; 8(4): 337-46.
  • 48. Oh E.Y., Ansell C., Nawaz H., Yang C.H., Wood P.A., Hrushesky W.J. Global breast cancer seasonality. Breast Cancer Res Treat. 2010; 123(1): 233-243.
  • 49. Cohen M., Lippman M., Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978; 2(8094): 814-816.
  • 50. Davis S., Mirick D.K. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control. 2006; 17(4): 539-545.
  • 51. Chen S.T., Choo K.B., Hou M.F., Yeh K.T., Kuo S.J., Chang J.G. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26(7): 1241-6.
  • 52. Schernhammer E.S., Hankinson S.E. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009; 18(1): 74-79.
  • 53. Nagata C., Nagao Y., Yamamoto S., Shibuya C., Kashiki Y., Shimizu H. Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. Cancer Epidemiol Biomarkers Prev. 2008; 17(6): 1418-1423.
  • 54. Schernhammer E.S., Berrino F., Krogh V. i wsp. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008; 100(12): 898-905.
  • 55. Kloog I., Haim A., Stevens R.G., Barchana M., Portnov B.A. Light at night codistributeswith incident breast but not lung cancer in the female population of Israel. Chronobiol Intl. 2008; 25: 65–81.
  • 56. Stevens R.G. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987; 125(4): 556-561.
  • 57. Hansen J. Risk of breast cancer after night- and shift work: current evidence and ongoing studies in Denmark. Cancer Causes Control. 2006; 17(4): 531-537.
  • 58. Davis S., Mieick D.K., Stevens G. Night shift work, Light at night, and risk of breast cancer. J Natl Cancer Inst. 2001; 93(20): 1557-1562.
  • 59. Schernhammer E.S., Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004; 90(5): 941–943.
  • 60. Hahn R.A. Profound bilateral blindness and the incidence of breast cancer. Epidemiology. 1991; 2(3): 208-210.
  • 61. Pukkala E., Verkasalo P.K., Ojamo M., Rudanko S.L. Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control. 1999; 10(1): 13-20.
  • 62. Feychting M., Osterlund B., Ahlbom A. Reduced cancer incidence among the blind. Epidemiology. 1998; 9(5): 490-494.
  • 63. Flynn-Evans E.E., Stevens R.G., Tabandeh H., Schernhammer E.S., Lockley S.W. Total visual blindness is protective against breast cancer. Cancer Causes Control. 2009; 20(9): 1753-1756.
  • 64. Verkasalo P.K., Lillberg K., Stevens R.G. Sleep Duration and Breast Cancer: A Prospective Cohort Study. Cancer Res. 2005; 65: 9595-9600.
  • 65. Wu A.H., Wang R., Koh W.P., Stanczyk F.Z., Lee H.P., Yu M.C. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis. 2008; 29: 1244-1248.
  • 66. Kakizaki M., Kuriyama S., Sone T. i wsp. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer. 2008; 99(9): 1502-1505.
  • 67. Erren T.C., Piekarski C. Does winter darkness in the Arctic protect against cancer? The melatonin hypothesis revisited. Med Hypotheses. 1999; 53: 1–5.
  • 68. Davis S., Kaune W.T., Mirick D.K., Chen C., Stevens R.G. Residential magnetic fi elds, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol. 2001; 154(7): 591-600.
  • 69. Girgert R., Hanf V., Emons G., Gründker C. Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fi elds. Bioelectromgnetics. 2010; 31(3): 237-245.
  • 70. Chen C., Ma X., Zhong M., Yu Z. Extremely low-frequency electromagnetic fi elds exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls. Breast Cancer Res Treat. 2010; 123(2): 569-576.
  • 71. Kolstad H.A. Nightshift work and risk of breast cancer and other cancers--a critical review of the epidemiologic evidence. Scand J Work Environ Health. 2008; 34(1): 5-22.
  • 72. Travis R.C., Allen D.S., Fentiman I.S., Key T.J. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004; 96(6): 475-482.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-cb068e53-a442-42c0-9a29-606d2c896cfe
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.